Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. The additional approval would expand Medicare coverage for Wegovy and coverage by other insurers for such adults with heart conditions.
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript February 8, 2024 Veru Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Veru Inc. Investor Conference Call. [Operator Instructions] Please note, this […]